Doctor Pierpaolo Pellicori

Doctor Pierpaolo Pellicori

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

Member of:

I am a clinical cardiologist currently working as a senior clinical research fellow in the Robertson Centre for Biostatistics at the University of Glasgow with an honorary consultant cardiologist contract with NHS Greater Glasgow and Clyde. I obtained my medical degree from Sapienza University in Rome and completed my specialist training in Cardiology in 2008 from the same institution. I spent my last 9 months of training abroad at a tertiary centre (RWTH University, Aachen, Germany) to improve my skills in advanced echocardiography. I subsequently worked for 6 months with an Italian Charity (Emergency) in Sudan and then applied for GMC registration before moving to the UK in 2010. Over the past ten years, I have combined both research and clinical duties. My current area of interest is the use of new imaging modalities as tool to quantify clinical congestion with greater precision.

Presentations Events

Neutrophil-to-lymphocyte ratio: association with indices of congestion, inflammation, and mortality in outpatients with heart failure

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure - epidemiology, prognosis, outcome 1

Access

The burden and pattern of comorbidities and its relation to mortality in frail vs non-frail patients with chronic heart failure

Event: ESC Congress 2022

Topic: Comorbidities

Session: Chroninc heart failure - Comorbidities

Access

Fluid responsiveness and congestion.

Event: EuroEcho 2019

Topic: Echocardiography, Other

Session: Non-invasive hemodynamic assessment in different contexts

Access

Body mass index or waist and hip circumference as predictors of outcome in the UK biobank

Event: ESC Congress 2019

Topic: Epidemiology

Session: New approaches in risk stratification

Access

Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Heart failure: prognosis, outcome

Access

Relationship between congestion by ultrasound, body mass index and cardiac rhythm in ambulatory patients with heart failure

Event: Heart Failure 2019

Topic: Imaging

Session: Chronic Heart Failure – Diagnostic Methods

Access

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Chronic heart failure – Treatment

Access

HsCRP in patients with heart failure and its associations with outcome

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure – epidemiology, prognosis, outcome

Access

Relationship of clinical congestion to biomarker activation and outcome in patients with heart failure: findings from BIOSTAT-CHF

Event: Heart Failure 2018

Topic: Clinical

Session: Congestion: how to detect with new technologies

Access

Relationship of circulating plasma levels of D-Dimer and outcome in patients with heart failure: findings from BIOSTAT-CHF

Event: Heart Failure 2018

Topic: Pathophysiology and Mechanisms

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access

Doctor Pierpaolo Pellicori

Biography

Contributor content

Neutrophil-to-lymphocyte ratio: association with indices of congestion, inflammation, and mortality in outpatients with heart failure

The burden and pattern of comorbidities and its relation to mortality in frail vs non-frail patients with chronic heart failure

Fluid responsiveness and congestion.

Body mass index or waist and hip circumference as predictors of outcome in the UK biobank

Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

Relationship between congestion by ultrasound, body mass index and cardiac rhythm in ambulatory patients with heart failure

What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels

HsCRP in patients with heart failure and its associations with outcome

Relationship of clinical congestion to biomarker activation and outcome in patients with heart failure: findings from BIOSTAT-CHF

Relationship of circulating plasma levels of D-Dimer and outcome in patients with heart failure: findings from BIOSTAT-CHF

ESC 365 is supported by